Kortuc Inc. Closed Financing From Axa Japan To Accelerate Pivotal Phase Ii Study Of Novel Radiosensitizer For Cancer Radiotherapy
Kortuc Inc. Closed Financing From Axa Japan To Accelerate Pivotal Phase Ii Study Of Novel Radiosensitizer For Cancer Radiotherapy
07/29/21, 12:07 PM
Location
londonToday KORTUC Inc., a Japanese clinical-stage biopharmaceutical company focusing on the clinical and product development of a novel radiosensitizer improving the effectiveness of cancer radiotherapy (RT), announces the closing of an equity investment from AXA Japan.
Company Info
Location
london, ontario, canada
Additional Info
KORTUC will use the financing to fund Research and Development activities, accelerate its Pivotal Phase II Study in the UK and pursue additional Pivotal Studies in the US. Boris Moutier, Corporate Officer of AXA Japan, Japan and Asia Chief Investment Officer, also highlights that “With this brand new radiosensitizer, KORTUC has great potential to become a ground-breaking player in cancer treatment field, and we are glad to engage in this greatly promising journey.